Home » Stocks » CYCN

Cyclerion Therapeutics, Inc. (CYCN)

Stock Price: $3.33 USD 0.11 (3.42%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
After-hours: $3.30 -0.03 (-0.90%) Jan 19, 7:49 PM
Market Cap 109.36M
Revenue (ttm) 3.64M
Net Income (ttm) -84.63M
Shares Out 32.10M
EPS (ttm) -2.94
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $3.33
Previous Close $3.22
Change ($) 0.11
Change (%) 3.42%
Day's Open 3.25
Day's Range 3.23 - 3.43
Day's Volume 188,926
52-Week Range 2.25 - 8.39

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 weeks ago

CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing innovative medicines for people with seri...

GlobeNewsWire - 4 weeks ago

Anjeza Gjino promoted to Chief Financial Officer; Bill Huyett to transition to Strategic Advisor

GlobeNewsWire - 2 months ago

Positive IW-6463 translational pharmacology study in healthy elderly subjects showed significant i mprovements in multiple measures associated with age-related cognitive decline and neurodegen...

The Motley Fool - 3 months ago

A second midstage failure is hurting the biotech's stock price today.

GlobeNewsWire - 3 months ago

Showed significant i mprovements in neurophysiological and objective performance measures associated with age-related cognitive decline and neurodegenerative diseases

GlobeNewsWire - 3 months ago

Study results do not support further internal development Study results do not support further internal development

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate c...

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments for serious and orphan disea...

GlobeNewsWire - 5 months ago

-  IW-6463 and olinciguat top line clinical study results remain on track for late summer and late Q3 2020, respectively   -

GlobeNewsWire - 5 months ago

 -  Additional capital to accelerate clinical development of IW-6463 in two CNS indications and olinciguat for sickle cell disease  -

GlobeNewsWire - 6 months ago

CAMBRIDGE, Mass., July 17, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments for serious and orphan disea...

GlobeNewsWire - 9 months ago

– Closed enrollment for olinciguat Phase 2 STRONG SCD study for sickle cell disease; topline data readout expected Q3 2020 –

GlobeNewsWire - 1 year ago

– Management to review the Company's sGC clinical pipeline programs: praliciguat for diabetic nephropathy, olinciguat for sickle cell disease, and IW-6463 for neurodegenerative diseases –

Forbes - 1 year ago

The company evaluated praliciguat in 2 diseases, diabetic nephropathy and HFpEF, which are very complex and difficult-to-treat.

The Motley Fool - 1 year ago

A double clinical trial failure sends the biotech’s shares down.

Market Watch - 1 year ago

Shares of Cyclerion Therapeutics Inc. plummeted 71% toward a record low Wednesday, to pace all premarket losers, after the biopharmaceutical company said a Phase 2 trial of its diabetes treatm...

About CYCN

Cyclerion Therapeutics, a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. Its product candidates include Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection... [Read more...]

Industry
Biotechnology
CEO
Dr. Peter M. Hecht
Employees
94
Stock Exchange
NASDAQ
Ticker Symbol
CYCN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for CYCN stock is "Hold" and the 12-month stock price forecast is 4.00.

Price Target
$4.00
Analyst Consensus: Hold